share_log

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Rating of "Buy" From Analysts

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Rating of "Buy" From Analysts

泰莎基因療法公司(納斯達克代碼：TSHA)獲得分析師的平均評級為買入
Defense World ·  2022/09/05 16:32

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Rating) have been given a consensus rating of "Buy" by the eleven analysts that are covering the stock, Marketbeat Ratings reports. Ten analysts have rated the stock with a buy rating. The average 1 year target price among brokerages that have covered the stock in the last year is $24.20.

據市場評級公司報道，泰莎基因療法公司(納斯達克代碼：TSHA-GET Rating)的股票已被跟蹤該股票的11位分析師一致給予“買入”的評級。十位分析師對該股的評級為買入。在過去一年追蹤該股的券商中，1年目標價的平均水平為24.20美元。

Several research firms recently issued reports on TSHA. The Goldman Sachs Group lowered their price objective on Taysha Gene Therapies from $27.00 to $16.00 and set a "buy" rating on the stock in a report on Tuesday, May 24th. Needham & Company LLC lowered their price objective on Taysha Gene Therapies to $20.00 and set a "buy" rating on the stock in a report on Tuesday, May 17th. Wedbush lowered their price objective on Taysha Gene Therapies from $9.00 to $5.00 and set an "outperform" rating on the stock in a report on Friday, August 12th. Guggenheim lowered their price objective on Taysha Gene Therapies to $22.00 and set a "na" rating on the stock in a report on Tuesday, May 17th. Finally, Chardan Capital lowered their price objective on Taysha Gene Therapies from $34.00 to $32.00 and set a "buy" rating on the stock in a report on Friday, August 12th.

幾家研究公司最近發佈了關於TSHA的報告。在5月24日週二的一份報告中，高盛夫婦將塔莎基因療法的目標價從27.00美元下調至16.00美元，並對該股設定了買入評級。Needham&Company LLC在5月17日(星期二)的一份報告中將塔莎基因療法的目標價下調至20.00美元，並對該股設定了“買入”評級。韋德布什在8月12日星期五的一份報告中將塔莎基因療法的目標價從9.00美元下調至5.00美元，並對該股設定了“跑贏大盤”的評級。古根海姆在5月17日(星期二)的一份報告中將塔莎基因療法的目標價下調至22.00美元，並對該股設定了“NA”評級。最後，查丹資本將泰莎基因療法的目標價從34.00美元下調至32.00美元，並在8月12日(星期五)的一份報告中對該股設定了“買入”評級。

Get
到達
Taysha Gene Therapies
泰莎基因療法
alerts:
警報：

Taysha Gene Therapies Price Performance

泰莎基因療法的價格表現

NASDAQ:TSHA opened at $3.16 on Monday. Taysha Gene Therapies has a 52 week low of $2.33 and a 52 week high of $21.90. The company has a quick ratio of 1.79, a current ratio of 1.79 and a debt-to-equity ratio of 1.15. The stock has a market capitalization of $129.85 million, a PE ratio of -0.66 and a beta of 0.99. The stock's 50-day moving average price is $4.06 and its 200-day moving average price is $4.56.

納斯達克：臺灣證交所週一開盤報3.16美元。泰莎基因療法的52周低點為2.33美元，52周高位為21.90美元。該公司的速動比率為1.79，流動比率為1.79，債務權益比為1.15。該股市值為1.2985億美元，市盈率為-0.66，貝塔係數為0.99。該股的50日移動均線價格為4.06美元，200日移動均線價格為4.56美元。

Insiders Place Their Bets

內部人士下注

In other news, CFO Kamran Alam sold 7,476 shares of Taysha Gene Therapies stock in a transaction that occurred on Thursday, August 18th. The shares were sold at an average price of $3.87, for a total transaction of $28,932.12. Following the sale, the chief financial officer now owns 290,645 shares of the company's stock, valued at approximately $1,124,796.15. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, CMO Suyash Prasad sold 23,923 shares of Taysha Gene Therapies stock in a transaction that occurred on Friday, July 1st. The shares were sold at an average price of $3.53, for a total transaction of $84,448.19. Following the sale, the chief marketing officer now owns 543,450 shares of the company's stock, valued at approximately $1,918,378.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Kamran Alam sold 7,476 shares of Taysha Gene Therapies stock in a transaction that occurred on Thursday, August 18th. The shares were sold at an average price of $3.87, for a total transaction of $28,932.12. Following the completion of the sale, the chief financial officer now owns 290,645 shares of the company's stock, valued at approximately $1,124,796.15. The disclosure for this sale can be found here. Insiders have sold 57,345 shares of company stock valued at $208,051 in the last ninety days. 42.40% of the stock is currently owned by corporate insiders.
在其他新聞方面，首席財務官卡姆蘭·阿拉姆在8月18日星期四的一筆交易中出售了7,476股泰莎基因療法公司的股票。這些股票以3.87美元的平均價格出售，總成交金額為28,932.12美元。出售後，首席財務官現在擁有290,645股公司股票，價值約1,124,796.15美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，可以通過以下鏈接訪問該文件。在其他新聞方面，CMO Suyash Prasad在7月1日星期五的一筆交易中出售了23,923股泰莎基因療法的股票。這些股票以3.53美元的平均價格出售，總成交金額為84,448.19美元。出售後，首席營銷官現在擁有543,450股公司股票，價值約1,918,378.50美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，可以通過以下鏈接訪問該文件。此外，首席財務官卡姆蘭·阿拉姆在8月18日星期四的一筆交易中出售了7,476股泰莎基因療法公司的股票。這些股票以3.87美元的平均價格出售，總成交金額為28,932.12美元。出售完成後，首席財務官現在擁有290,645股公司股票，價值約1,124,796.15美元。此次拍賣的披露信息可在此處找到。在過去的90天裏，內部人士已經出售了57,345股公司股票，價值208,051美元。42.40%的股份目前由企業內部人士持有。

Institutional Trading of Taysha Gene Therapies

塔莎基因療法的制度性交易

Several institutional investors have recently added to or reduced their stakes in TSHA. Northern Trust Corp increased its holdings in Taysha Gene Therapies by 1.4% in the 4th quarter. Northern Trust Corp now owns 214,970 shares of the company's stock valued at $2,504,000 after purchasing an additional 3,042 shares during the last quarter. ProShare Advisors LLC acquired a new stake in Taysha Gene Therapies in the 4th quarter valued at approximately $121,000. GSA Capital Partners LLP acquired a new stake in Taysha Gene Therapies in the 4th quarter valued at approximately $476,000. Virtus ETF Advisers LLC increased its holdings in Taysha Gene Therapies by 39.3% in the 4th quarter. Virtus ETF Advisers LLC now owns 11,519 shares of the company's stock valued at $134,000 after purchasing an additional 3,251 shares during the last quarter. Finally, 683 Capital Management LLC acquired a new stake in Taysha Gene Therapies in the 4th quarter valued at approximately $117,000. Institutional investors and hedge funds own 34.28% of the company's stock.

幾家機構投資者最近增持或減持了TSHA的股份。北方信託公司在第四季度增持了1.4%的塔莎基因療法。Northern Trust Corp目前持有214,970股該公司股票，價值2,504,000美元，此前該公司在上個季度又購買了3,042股。ProShare Advisors LLC在第四季度收購了塔莎基因療法公司的新股份，價值約為121,000美元。GSA Capital Partners LLP在第四季度收購了塔莎基因療法公司的新股份，價值約476,000美元。Virtus ETF Advisers LLC在第四季度增持了塔莎基因療法39.3%的股份。Virtus ETF Advisers LLC現在擁有11,519股該公司的股票，價值13.4萬美元，在上個季度又購買了3,251股。最後，683資本管理有限責任公司在第四季度收購了泰莎基因療法公司的新股份，價值約為11.7萬美元。機構投資者和對衝基金持有該公司34.28%的股票。

Taysha Gene Therapies Company Profile

泰莎基因療法公司簡介

(Get Rating)

(獲取評級)

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis.

泰莎基因療法公司是一家基因治療公司，專注於開發基於腺相關病毒的基因療法並將其商業化，用於治療中樞神經系統單基因疾病。它主要開發用於治療巨大軸索性神經病的TSHA-120；用於治療Rett綜合徵的TSHA-102；用於治療CLN1疾病的TSHA-121；用於治療CLN1疾病的TSHA-118；用於治療SLC13A5缺乏症的TSHA-105；以及用於治療GM2神經節苷脂缺乏的TSHA-101。

Featured Articles

專題文章

  • Get a free copy of the StockNews.com research report on Taysha Gene Therapies (TSHA)
  • Could Snap Stock Rebound As Management Restructures?
  • MarketBeat: Week in Review 8/29 – 9/2
  • Hormel Looks Cheap At These Levels
  • Lululemon Set To Soar Into September
  • Could Nike Stock be Oversold, but Still Overvalued?
  • 免費獲取StockNews.com關於塔莎基因療法的研究報告(TSHA)
  • 隨着管理層重組，股市能否迅速反彈？
  • MarketBeat：回顧中的一週8/29-9/2
  • 霍梅爾在這些水平上看起來很便宜
  • 露露檸檬將飆升至9月
  • 耐克股票會被超賣，但仍被高估嗎？

Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.

接受《泰莎基因療法日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊，接收最新新聞和分析師對塔莎基因療法和相關公司評級的每日簡要摘要。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論